Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
79 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Seizures - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Seizures - Pipeline Review, H1 2015', provides an overview of the Seizures's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Seizures, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seizures and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Seizures - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Seizures and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Seizures products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Seizures pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Seizures - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Seizures pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Seizures Overview 8 Therapeutics Development 9 Pipeline Products for Seizures - Overview 9 Pipeline Products for Seizures - Comparative Analysis 10 Seizures - Therapeutics under Development by Companies 11 Seizures - Therapeutics under Investigation by Universities/Institutes 13 Seizures - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Seizures - Products under Development by Companies 17 Seizures - Products under Investigation by Universities/Institutes 18 Seizures - Companies Involved in Therapeutics Development 19 Acorda Therapeutics, Inc. 19 Advicenne Pharma 20 Alexza Pharmaceuticals, Inc. 21 Concert Pharmaceuticals, Inc. 22 Neurelis, Inc. 23 Novartis AG 24 Pfizer Inc. 25 Sage Therapeutics 26 Ultragenyx Pharmaceutical Inc. 27 Upsher-Smith Laboratories, Inc. 28 Seizures - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Target 30 Assessment by Mechanism of Action 32 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Drug Profiles 38 ADV-6208 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 alprazolam - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 C-10068 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 CCG-63802 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 CHEC-9 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 diazepam - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 diazepam - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 diazepam - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 everolimus - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Gene Therapy to Activate Neuropeptide Y Receptor Y2 and Y5 for Epilepsy - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 midazolam hydrochloride - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 SAGE-217 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 UX-007 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Seizures - Recent Pipeline Updates 60 Seizures - Dormant Projects 70 Seizures - Discontinued Products 71 Seizures - Product Development Milestones 72 Featured News & Press Releases 72 Sep 02, 2014: SAGE Therapeutics Presents New Preclinical Data on SAGE-217 at Eilat Conference on New Anti-Epileptic Drugs 72 Nov 01, 2013: Systematic Review Finds Intranasal Midazolam Comparable To Intravenous Or Rectal Administration Of Diazepam For Treatment Of Acute Seizure Emergencies In Pediatric Patients 72 Jun 24, 2013: Upsher-Smith Labs Announces Patient Enrollment In Open-label Safety Study Of USL261 For Rescue Treatment Of Seizure Clusters In Epilepsy 73 May 06, 2013: Alexza Pharma To Present Data On AZ-002 At Antiepileptic Drug And Device Trials Conference 74 Mar 19, 2013: Upsher-Smith Labs Presents Favorable Phase I Data For USL261 At 65th Annual Meeting Of AAN 74 Nov 26, 2012: Upsher-Smith Labs Presents Clinical Data On Midazolam At American Epilepsy Society Annual Meeting 75 Apr 26, 2012: Upsher-Smith Provides Update On Phase III Seizure Clusters Study 76 Appendix 78 Methodology 78 Coverage 78 Secondary Research 78 Primary Research 78 Expert Panel Validation 78 Contact Us 78 Disclaimer 79
List of Tables Number of Products under Development for Seizures, H1 2015 9 Number of Products under Development for Seizures - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 12 Number of Products under Investigation by Universities/Institutes, H1 2015 13 Comparative Analysis by Late Stage Development, H1 2015 14 Comparative Analysis by Clinical Stage Development, H1 2015 15 Comparative Analysis by Early Stage Development, H1 2015 16 Products under Development by Companies, H1 2015 17 Products under Investigation by Universities/Institutes, H1 2015 18 Seizures - Pipeline by Acorda Therapeutics, Inc., H1 2015 19 Seizures - Pipeline by Advicenne Pharma, H1 2015 20 Seizures - Pipeline by Alexza Pharmaceuticals, Inc., H1 2015 21 Seizures - Pipeline by Concert Pharmaceuticals, Inc., H1 2015 22 Seizures - Pipeline by Neurelis, Inc., H1 2015 23 Seizures - Pipeline by Novartis AG, H1 2015 24 Seizures - Pipeline by Pfizer Inc., H1 2015 25 Seizures - Pipeline by Sage Therapeutics, H1 2015 26 Seizures - Pipeline by Ultragenyx Pharmaceutical Inc., H1 2015 27 Seizures - Pipeline by Upsher-Smith Laboratories, Inc., H1 2015 28 Assessment by Monotherapy Products, H1 2015 29 Number of Products by Stage and Target, H1 2015 31 Number of Products by Stage and Mechanism of Action, H1 2015 33 Number of Products by Stage and Route of Administration, H1 2015 35 Number of Products by Stage and Molecule Type, H1 2015 37 Seizures Therapeutics - Recent Pipeline Updates, H1 2015 60 Seizures - Dormant Projects, H1 2015 70 Seizures - Discontinued Products, H1 2015 71
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
